NCT06342986

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Masonic Cancer Center, University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.

Conditions

• Gynecologic Cancer
• Ovarian Cancer
• Fallopian Tube Cancer
• Primary Peritoneal Cavity Cancer

Interventions

Type	Name	Description
DRUG	FT536	FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.
DRUG	Fludarabine	Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.
DRUG	CY	CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.

Timeline

• Start date: 2024-07-11
• Primary completion: 2026-03-26
• Completion: 2027-06-30
• First posted: 2024-04-02
• Last updated: 2026-04-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study